NCT06742762View on ClinicalTrials.gov

A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 17, 2024

Primary Completion Date

April 20, 2025

Study Completion Date

April 20, 2025

Conditions
Renal Impairment
Interventions
DRUG

AZD5004

Dose 1

Trial Locations (3)

32808

Research Site, Orlando

32809

Research Site, Orlando

33014

Research Site, Miami Lakes

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY